Scholars@Duke
James Abbruzzese

James Abbruzzese

D.C.I. Distinguished Professor Emeritus of Medical Oncology
Medicine, Medical Oncology
james.abbruzzese@duke.edu
440 Mudd Building, Box 3406, Durham, NC 27710
440 Mudd Building, Box 3406, Durham, NC 27710

Scholarly Works - Conferences

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Conference Ann Surg Oncol · February 2025 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2671 Background: MERTK is a receptor tyrosine kinase from the tumor-associated macrophage kinase (TAMK) family that regulates key aspects of immune homeostasis and responses to infection. MERTK inhibition may lower the thresho ... Full text Cite

Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

Conference Molecular Cancer Therapeutics · December 1, 2019 AbstractBackground: The combination of cediranib (ced) and olaparib (olap) improves progression-free survival and overall response rates (ORR) in women with recurrent plat sensitive high-grade serous (HGS) o ... Full text Cite

Abstract 891: FGF21 prevents high fat diet-induced pancreatic cancer in mice expressing oncogenic Kras

Conference Cancer Research · August 1, 2015 AbstractThe genetic landscape of pancreatic cancer shows nearly ubiquitous mutations of Kras. However, expression of mutant Kras alone is not sufficient to drive pancreatic ductal adenocarcinoma (PDAC) in ad ... Full text Cite

Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.

Conference Ann Surg Oncol · April 2009 INTRODUCTION: Actual 5-year survival rates of 10-18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in these series. We evaluated long-term survival and patterns of recurrence ... Full text Link to item Cite

Highlights of the 2008 San Antonio Breast Cancer Symposium.

Conference Clin Adv Hematol Oncol · January 2009 Link to item Cite

Pancreatic cancer.

Conference Lancet · March 27, 2004 Pancreatic cancer remains a major unsolved health problem, with conventional cancer treatments having little impact on disease course. Almost all patients who have pancreatic cancer develop metastases and die. The main risk factors are smoking, age, and so ... Full text Link to item Cite

Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.

Conference Semin Oncol · December 2002 Pancreatic cancer continues to be a challenging therapeutic problem, with approximately 28,000 deaths annually in the United States. Most studies of single-agent or combination chemotherapy in the treatment of patients with advanced adenocarcinoma of the p ... Full text Link to item Cite

Epidermal growth factor receptor-targeted therapy for pancreatic cancer.

Conference Semin Oncol · October 2002 Epidermal growth factor receptor (EGFR) plays an important role in tumor development and maintenance. It is a cell surface molecule that mediates signal transduction from the cell surface to cytoplasm. Elevated expression of EGFR or its ligand correlates w ... Full text Link to item Cite

Cancer: Introduction

Conference Cancer · August 15, 2002 Full text Cite

New applications of gemcitabine and future directions in the management of pancreatic cancer.

Conference Cancer · August 15, 2002 Gemcitabine has been reported to be an active agent in pancreatic cancer. Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at ... Full text Link to item Cite

Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.

Conference Ann N Y Acad Sci · June 30, 1999 The tumor suppressor gene deleted in pancreatic cancer locus 4 (Smad4/DPC4) is inactivated in about 50% of pancreatic adenocarcinomas. The role of DPC4 in the transforming growth factor-beta (TGF-beta) receptor-mediated signal transduction cascade in human ... Full text Link to item Cite

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.

Conference Front Biosci · November 1, 1998 Adjuvant 5-fluorouracil and concurrent radiation may improve survival following complete surgical resection in patients with pancreatic adenocarcinoma. However, the morbidity and prolonged recovery associated with pancreaticoduodenectomy frequently prevent ... Full text Link to item Cite